Page 73 - Read Online
P. 73

Page 10 of 12            Cepas-Guillen et al. Vessel Plus 2021;5:26  https://dx.doi.org/10.20517/2574-1209.2020.79

               Multi-slice cardiac CT is used to assess the potential for LVOT obstruction and the degree of mitral annular
               calcification [50,51] .

               Mitral regurgitation is often coexistent with other cardiac disease, such as tricuspid regurgitation, severe
                                                                      [48]
               pulmonary hypertension, and severe left ventricle disfunction . Despite the increasing availability of
               TMVR, patients with severe mitral regurgitation may not be eligible. Niikura et al.  showed that the
                                                                                         [52]
               ineligibility rate for TMVR is usually very high (89.0%). The most common reasons for TMVR exclusion
               were excessive frailty (15.3%), severe tricuspid regurgitation (15.3%), and prior aortic valve therapy (14.2%).
               Mitral anatomic exclusions were present in 15.8%, with severe annular calcification in 7.4%, and risk for
               LVOT obstruction was notably infrequent (4.4%). They showed that those patients ineligible for TMVR and
               treated medically have poor outcomes: cardiac death was 11.8% and death or heart failure hospitalization
               was 22.4% at one year. These data support the need for development of alternative management with
               optimal medical treatment, with the goal of improving the prognosis of these patients.


               CONCLUSION
               Current percutaneous mitral devices are emerging as a feasible less invasive alternative for patients with
               severe MR. The anatomical complexity of MV and the coexistence of various mechanisms of MR might
               limit the effectiveness of a unique technique for the treatment of severe MR. Along with the optimal medical
               therapy and the appropriate candidate selection by the heart team, the use of combined percutaneous
               techniques may be necessary in the future to optimize results and improve long-term outcomes. Upcoming
               trials are expected to address knowledge gaps, improving their safety and efficacy. The knowledge of this
               constantly evolving technology by clinical and interventional cardiologists might significantly improve
               patient outcomes.

               DECLARATIONS
               Authors’ contributions
               Article conception and design: Cepas-Guillen PL, Flores-Umanzor E, Regueiro A, Freixa X
               Acquisition and analysis of bibliographic information: Cepas-Guillen PL, Flores-Umanzor E
               Drafting of the manuscript: Cepas-Guillen PL, Flores-Umanzor E
               Critical revision and final approval of the manuscript: Regueiro A, Freixa X

               Availability of data and materials
               Not applicable.

               Financial support and sponsorship
               None.


               Conflicts of interest
               All authors declared that there are no conflicts of interest.


               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.
   68   69   70   71   72   73   74   75   76   77   78